Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Am J Trop Med Hyg ; 58(3): 358-64, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9546419

ABSTRACT

While the parenteral iron-chelating agent desferrioxamine B has anti-malarial activity in humans, the usefulness of an orally active chelator for this indication has not been investigated previously in vivo. We conducted a prospective, double-blind, placebo-controlled, cross-over trial of deferiprone (L1; CP20; 1,2-dimethyl-3-hydroxypyridin-4-one) in 25 adult Zambians with asymptomatic Plasmodium falciparum parasitemia. Deferiprone was administered daily for three or four days in divided doses of 75 or 100 mg/kg of body weight, dosages that are effective for treating iron overload. No reduction in asexual intra-erythrocytic parasites was observed during or after deferiprone treatment. The mean peak plasma concentration of deferiprone (108.9 +/- 24.9 micromol/L) achieved was within the range demonstrated to inhibit the growth of P. falciparum in vitro, but the systemic exposure as determined by the 24-hr plasma concentration-time curve would not be predicted inhibit growth in vivo. No evidence of deferiprone-associated hematological toxicity was noted in this short-term study of these subjects, all of whom had clinical evidence of normal body iron stores. Because of the risk of neutropenia and other adverse effects with higher doses or prolonged use of the chelator, additional trials of deferiprone as a sole anti-malarial agent would not seem to be justified. In contrast, further efforts are needed to develop other orally active iron-chelating agents specifically for their anti-malarial action.


Subject(s)
Iron Chelating Agents/therapeutic use , Malaria, Falciparum/drug therapy , Parasitemia/drug therapy , Pyridones/therapeutic use , Administration, Oral , Adult , Area Under Curve , Cross-Over Studies , Deferiprone , Dose-Response Relationship, Drug , Double-Blind Method , Humans , Iron Chelating Agents/administration & dosage , Iron Chelating Agents/pharmacokinetics , Malaria, Falciparum/metabolism , Male , Parasitemia/metabolism , Prospective Studies , Pyridones/administration & dosage , Pyridones/pharmacokinetics
2.
Can J Physiol Pharmacol ; 76(9): 895-9, 1998 Sep.
Article in English | MEDLINE | ID: mdl-10066140

ABSTRACT

While conducting studies on the prevention of mortality from acute iron intoxication in rats, diazepam, given to prevent animal suffering, was observed to be associated with reduced mortality in a limited number of animals. The objective was to assess whether diazepam reduces mortality following acute iron intoxication in rats. Survival of rats was compared among groups receiving (i) orally 612 mg/kg iron alone (LD60), (ii) iron with a subcutaneous injection of 2.5 mg/kg diazepam (DZ), or (iii) iron, DZ with 800 mg/kg deferiprone intraperitoneal injections. The administration of DZ decreased mortality from 60 to 16% (p < 0.001). The addition of deferiprone to DZ resulted in zero mortality (p < 0.05 compared with the DZ group) over the study period. The administration of DZ was not associated with decreased iron absorption or increased urinary iron excretion, whereas the administration of deferiprone did result in urinary iron excretion. Microscopic examination suggests that diazepam administration may be associated with lower intracellular accumulation of iron. In conclusion, diazepam reduces mortality from iron overdose in rats through a yet unidentified mechanism, although the drug does not inhibit iron absorption or enhance urinary iron removal.


Subject(s)
Diazepam/therapeutic use , Iron Overload/drug therapy , Acute Disease , Animals , Iron/blood , Iron/urine , Male , Rats , Rats, Wistar
3.
Int J Clin Pharmacol Ther ; 34(7): 288-92, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8832304

ABSTRACT

Recently, we demonstrated that administration of the orally active iron chelating agent deferiprone (1,2-dimethyl-3-hydroxypyrid-4-one (L1)) at 6-hour intervals results in significantly greater urinary iron excretion than that induced during administration of the drug at 12-hour intervals. That study was conducted in thalassemia patients, all of whom had received a packed red cell transfusion of 15 cc/kg. 72 hours prior to evaluation of urinary iron excretion, at a time when endogenous erythropoiesis would be expected to be at its lowest. In clinical practice however, thalassemia patients, suppression of endogenous erythropoiesis is not sustained between transfusions. We set out to determine the influence that administration of deferiprone has on urinary iron excretion at lower hemoglobin concentrations, immediately prior to transfusion. We hypothesized that hemoglobin levels will affect the ability of deferiprone to chelate iron. Ten regularly transfused patients with homozygous beta-thalassemia (HBT) aged mean +/- SD, 20.9 +/- 4.7, range 13 - 27 years, receiving long-term therapy with deferiprone, were treated with deferiprone 75 mg/kg/day, administered every 6 hours (or every 12 hours) for 72 hours immediately prior to a blood transfusion in the first month. One month later each patient received the other of the 2 dosing regimens for 72 hours immediately prior to transfusion. The deferiprone-induced 24-hour urinary iron excretion was similar during both dosing regimens; 0.56 +/- 0.45 mg/kg when L1 was given every 6 hours and 0.48 +/- 0.52 mg/kg when L1 was administered every 12 hours (p = 0.79). However, the calculated 24-hour area under the plasma concentration-time curve (AUC0-24) of deferiprone was significantly lower when deferiprone was administered at 6-hour intervals (6,762.8 +/- 1,601.6 mg*min/l), than that observed when deferiprone was administered every 12 hours (8,250.1 +/- 1,235.7 mg*min/l) (p = 0.04). The pharmacokinetics of deferiprone when administered immediately prior to transfusions are different from those following transfusions. More studies assessing total body iron excretion are needed to determine the contribution of the fecal route in iron excretion.


Subject(s)
Hemoglobins/metabolism , Iron Chelating Agents/pharmacology , Iron Chelating Agents/pharmacokinetics , Pyridones/pharmacology , Pyridones/pharmacokinetics , Adolescent , Adult , Area Under Curve , Deferiprone , Erythrocyte Transfusion , Half-Life , Humans , Iron/urine , Spectrophotometry, Atomic , Thalassemia/blood , Thalassemia/therapy
4.
J Toxicol Clin Toxicol ; 34(3): 279-87, 1996.
Article in English | MEDLINE | ID: mdl-8667465

ABSTRACT

BACKGROUND: Deferiprone [(1,2-dimethyl-3-hydroxypyrid-4-one) (L1)], is the first orally active iron chelating agent to reach clinical trials in patients with chronic iron overload. Its efficacy in preventing morbidity and mortality in acute iron poisoning has not been tested. OBJECTIVE: To determine whether deferiprone can reduce the mortality of rats following toxic oral doses of iron. METHODS: Rats were administered 612 mg/kg elemental iron by gavage, corresponding to the LD58. A parallel group received the same oral dose of iron followed by deferiprone intraperitoneally at 400 mg/kg (loading dose), followed by additional intraperitoneal injections of 200 mg/kg, 100 mg/kg and 100 mg/kg of deferiprone at one hour intervals. RESULTS: Coadministering deferiprone with the iron decreased mortality from 58% (11/19) to 15% (3/20) (p = 0.013). The administration of deferiprone was associated with urinary excretion of iron (which did not occur with iron alone) and the production of the red deferiprone-iron complex. On histological examination there appeared to be less iron in the liver and gastrointestinal tract. CONCLUSION: The coadministration of deferiprone can decrease morbidity and mortality caused by acute iron overdose. Deferiprone holds promise for the treatment of iron poisoning but additional study is required.


Subject(s)
Iron Chelating Agents/therapeutic use , Iron/poisoning , Pyridones/therapeutic use , Animals , Deferiprone , Duodenum/chemistry , Injections, Intraperitoneal , Iron/metabolism , Male , Poisoning/drug therapy , Poisoning/mortality , Rats , Rats, Wistar , Stomach/chemistry , Survival Rate , Tissue Distribution
5.
Drug Alcohol Depend ; 39(1): 1-6, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7587968

ABSTRACT

Pentylenetetrazol (PTZ) and sodium valproate (VPA) produce acutely in the naive rat various behavioural effects resembling signs of opiate withdrawal in the morphine-treated subject. Suggestions in the literature that these substances may activate directly some of the neural consequences of opiate and drug withdrawal prompted us to look for and examine possible aversive effects of these substances at non-toxic doses. With a sensitive two-flavour, three-trial taste aversion procedure, relatively low doses of PTZ and VPA (5 and 160 mg/kg, respectively) do indeed have aversive effects. The maximum aversions were produced by 10 and 20 mg/kg PTZ and 320 mg/kg VPA and were equivalent to those of morphine withdrawal precipitated by 0.01-0.03 mg/kg naloxone in a morphine pellet-implanted animal. Moreover, the maximum aversions with PTZ and VPA were significantly higher than the maximum aversions seen with naloxone in the drug-naive animal under the same training conditions. Thus, the data from the present study confirmed the notion that low doses of PTZ and VPA in the naive animal may activate processes activated by drug withdrawal, including those important for the motivational effect of withdrawal. However, it was also pointed out that the lowest dose VPA producing aversion was higher than that found here to produce writhes and ataxia (80 mg/kg) but the same as that required for shaking (160 mg/kg), while the PTZ aversion was at a dose lower than that known to produce a PTZ cue. Implications were discussed for using withdrawal-like phenomena as a model in the non-treated organism of clinically-relevant withdrawal effects.


Subject(s)
Disease Models, Animal , Motivation , Opioid-Related Disorders/psychology , Pentylenetetrazole/toxicity , Substance Withdrawal Syndrome/psychology , Valproic Acid/toxicity , Animals , Avoidance Learning/drug effects , Conditioning, Classical/drug effects , Dose-Response Relationship, Drug , Male , Morphine Dependence/psychology , Naloxone/pharmacology , Neurologic Examination/drug effects , Rats , Rats, Sprague-Dawley , Taste/drug effects
6.
CMAJ ; 150(10): 1611-5, 1994 May 15.
Article in English | MEDLINE | ID: mdl-8174031

ABSTRACT

OBJECTIVE: To assess and compare the quality of nonstructured and structured abstracts of original research articles in three medical journals. DESIGN: Blind, criterion-based observational study. SAMPLE: Random sample of 300 abstracts (25 abstracts per journal each year) of articles published in the British Medical Journal (BMJ), the Canadian Medical Association Journal and the Journal of the American Medical Association (JAMA) in 1988 and 1989 (nonstructured abstracts) and in 1991 and 1992 (structured abstracts). MAIN OUTCOME MEASURES: The quality of abstracts was measured against 33 objective criteria, which were divided into eight categories (purpose, research design, setting, subjects, intervention, measurement of variables, results and conclusions). The quality score was determined by dividing the number of criteria present by the number applicable; the score varied from 0 to 1. RESULTS: The overall mean quality scores for nonstructured and structured abstracts were 0.57 and 0.74 respectively (p < 0.001). The frequency in meeting the specific criteria was generally higher for the structured abstracts than for the nonstructured ones. The mean quality score was higher for nonstructured abstracts in JAMA than for those in BMJ (0.60 v. 0.54, p < 0.05). The scores for structured abstracts did not differ significantly between the three journals. CONCLUSIONS: The findings support recommendations that promote the use of structured abstracts. Further studies should be performed to assess the effect of time on the quality of abstracts and the extent to which abstracts reflect the content of the articles.


Subject(s)
Abstracting and Indexing/standards , Periodicals as Topic
7.
Blood ; 83(8): 2329-33, 1994 Apr 15.
Article in English | MEDLINE | ID: mdl-8161801

ABSTRACT

Several life-threatening complications of the common disorder sickle cell disease require management with red blood cell transfusions and, hence, long-term iron-chelating therapy. The efficacy of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) has not previously been determined in patients with sickle cell disease. We compared the efficacy of L1 to that of standard-dose subcutaneous deferoxamine in four regularly transfused patients with homozygous sickle cell disease, who had evidence of severe iron overload and a history of poor compliance with deferoxamine. Determination of 24-hour urinary iron excretion conducted over 5 days immediately after transfusion showed that the mean daily urinary iron excretion induced by L1 at 75 mg/kg/d (0.48 +/- 0.23 mg/kg) was equivalent to that induced by deferoxamine at 50 mg/kg/d (0.39 +/- 0.06 mg/kg). In two of three patients studied, a significant (P < .025) increase in mean daily urinary iron excretion was achieved when the dose of L1 was increased to 100 mg/kg/d. Total iron balance studies, which quantitated both urinary and stool iron excretion on L1 and deferoxamine, determined that mean total daily iron excretion induced by deferoxamine (0.88 +/- 0.05 mg/kg) was significantly greater (P < .05) than that induced by L1 (0.53 +/- 0.17 mg/kg), attributable to the significantly greater stool iron excretion during deferoxamine treatment (0.50 +/- 0.16 mg/kg/d) compared with that measured during L1 treatment (0.12 +/- 0.08 mg/kg/d, P < .01). Stool iron excretion accounted for a significantly greater percentage of total iron excretion during deferoxamine treatment (59% +/- 20%) than during L1 treatment (23% +/- 14%, P < .01). These iron balance studies are the first to compare total iron excretion induced by L1 with that achieved by deferoxamine. They demonstrate that the mean total daily iron excretion during L1 treatment (0.53 +/- 0.17 mg/kg) is sufficient to maintain net negative iron balance in most regularly transfused patients with sickle cell disease. Because long-term compliance with L1 has been shown previously to be superior to that with deferoxamine in patients with homozygous beta-thalassemia, the use of L1 should increase the long-term effectiveness of iron chelation in patients with sickle cell disease.


Subject(s)
Anemia, Sickle Cell/metabolism , Iron Chelating Agents/therapeutic use , Iron/metabolism , Pyridones/therapeutic use , Administration, Oral , Adolescent , Anemia, Sickle Cell/drug therapy , Child , Deferiprone , Deferoxamine/therapeutic use , Dose-Response Relationship, Drug , Female , Humans
8.
Clin Pharmacol Ther ; 55(1): 70-5, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8299320

ABSTRACT

OBJECTIVE: To examine the effect of frequency of oral administration of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) on urinary iron excretion. HYPOTHESIS: Sustained serum concentrations of L1 will cause more iron chelation than the same daily dose given in larger but less frequent amounts. PATIENTS AND METHODS: Ten patients with thalassemia with a mean age of 20.9 +/- 4.7 years (range, 13 to 27 years), who were receiving regular treatment with 75 to 100 mg/kg/day oral L1, received 75 mg/kg/day L1 orally in equally divided doses: every 6 hours for 3 days and every 12 hours for 3 days. The two study periods occurred 1 month apart immediately after the monthly blood transfusions. Urine was collected for two consecutive 24-hour periods during each of the different schedules. Serial blood samples were collected from six patients over a 6-hour period and analyzed for total L1 and the L1 glucuronide metabolite concentrations. RESULTS: The patient's mean hemoglobin levels (138.8 +/- 12.5 and 139.0 +/- 11.6 gm/L) and ferritin levels (2856.4 +/- 2207.8 and 2890.0 +/- 2264.4 micrograms/L) were similar during the every-6-hour and every-12-hour L1 administrations, respectively. There was significantly more urinary iron excretion when L1 was administered every 6 hours (0.59 +/- 0.29 mg/kg/day) versus every 12 hours (0.40 +/- 0.26 mg/kg/day; p = 0.0129). Calculated 24-hour area under the plasma concentration-time curve of L1 was similar during the every-6-hour (7023.9 +/- 2637.8 mg.min/L) and every-12-hour (7050.1 +/- 1668.8 mg.min/L) experiments. CONCLUSIONS: These data suggest that the sustained presence of L1 in the blood results in greater chelation of iron than that observed with larger, less frequent doses.


Subject(s)
Iron Chelating Agents/metabolism , Iron/urine , Pyridones/administration & dosage , beta-Thalassemia/drug therapy , Administration, Oral , Adolescent , Adult , Deferiprone , Drug Administration Schedule , Ferritins/blood , Hemoglobins/analysis , Humans , Pyridones/pharmacokinetics , Pyridones/therapeutic use , beta-Thalassemia/metabolism
9.
J Neurochem ; 56(1): 192-8, 1991 Jan.
Article in English | MEDLINE | ID: mdl-1987318

ABSTRACT

The neuronal dopamine transporter/uptake site can be covalently labeled with the photoaffinity probe 1-(2-[bis-(4-fluorophenyl) methoxy]ethyl)-4-[2-(4-azido-3-[125I]iodophenyl)ethyl]piperazine [( 125I]FAPP) and visualized following sodium dodecyl sulfate polyacrylamide gel electrophoresis and autoradiography. Upon photolysis, [125I]FAPP specifically incorporated into a polypeptide of apparent Mr = 62,000 in membranes from both the putamen and the caudate nucleus of control, Alzheimer's, schizophrenia, and Huntington's diseased brain, and following complete deglycosylation, migrated as an Mr approximately 48,000 polypeptide. In parkinsonian postmortem putamen, however, there was no detectable photoincorporation of [125I]FAPP into the ligand binding subunit of the dopamine transporter. [125I]FAPP did specifically label the Mr 62,000 polypeptide of parkinsonian caudate, although with efficiencies of 20-50% of control. The asymmetrical loss of the dopamine transporter in Parkinson's diseased striatum was confirmed in reversible receptor binding experiments using [3H]GBR-12935 (3H-labeled 1-[2-(diphenylmethoxy) ethyl]-4-(3-phenylpropyl)piperazine). In parkinsonian putamen, mazindol competitively inhibited the binding of [3H]GBR-12935 with an estimated affinity (Ki approximately 2,000 nM) 10 times lower than in controls (Ki approximately 30 nM), while the affinity of maxindol for [3H]GBR-12935 binding in the caudate was equal to that seen with controls (Ki approximately 50 nM). The proportion of [3H]GBR-12935 binding sites recognized by mazindol with high affinity in Parkinson's diseased caudate was, however, reduced by 50-80%.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Carrier Proteins/metabolism , Caudate Nucleus/metabolism , Membrane Glycoproteins , Membrane Transport Proteins , Nerve Tissue Proteins , Parkinson Disease/metabolism , Putamen/metabolism , Affinity Labels , Aged , Azides/metabolism , Binding Sites , Binding, Competitive , Chromatography , Dopamine Plasma Membrane Transport Proteins , Humans , Mazindol/metabolism , Middle Aged , Molecular Weight , Photochemistry , Piperazines/metabolism , Wheat Germ Agglutinins
10.
Pharmacol Biochem Behav ; 35(1): 219-24, 1990 Jan.
Article in English | MEDLINE | ID: mdl-1969164

ABSTRACT

In rats, cessation of periodic injections of morphine reduces a preference for a palatable saccharin solution presented in a choice with water, and this has been interpreted to reflect withdrawal malaise. We confirmed and examined this "Parker and Radow Model" using subcutaneously implanted osmotic minipumps as the means of drug delivery and the opiate, sufentanil, and the psychostimulant, amphetamine, as the treatment drugs; surgical removal of the pumps was used to initiate withdrawal. Thus, rats withdrawn after 2 weeks exposure to a sufentanil-delivering pump (0.25 microgram/hr) showed a decreased preference for the saccharin and animals exposed to an amphetamine pump (68 micrograms/hr) showed an increased preference, as compared to placebo-exposed controls. This pattern of effects was systematically replicated in new subjects using 4 weeks of treatment and 136 micrograms/hr amphetamine. Since the locomotor increasing and body weight decreasing effects of amphetamine were also demonstrated and the doses of amphetamine and sufentanil were in comparable dose ranges, it was concluded that the Parker and Radow procedure may be a reliable measure of opiate withdrawal, but under similar test and treatment conditions other processes may be operative in amphetamine-treated animals. Problems of measuring motivation of withdrawal, particularly of spontaneous withdrawal, were noted.


Subject(s)
Analgesics, Opioid/adverse effects , Choice Behavior/drug effects , Dextroamphetamine/adverse effects , Fentanyl/analogs & derivatives , Substance Withdrawal Syndrome/psychology , Analgesics, Opioid/administration & dosage , Animals , Body Weight/drug effects , Dextroamphetamine/administration & dosage , Fentanyl/administration & dosage , Fentanyl/adverse effects , Infusion Pumps , Male , Rats , Rats, Inbred Strains , Sufentanil , Taste/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...